NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Price, News & Analysis $6.59 -0.01 (-0.15%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$6.58▼$6.6050-Day Range$2.34▼$6.6252-Week Range$2.30▼$19.01Volume1.57 million shsAverage Volume2.58 million shsMarket Capitalization$690.76 millionP/E RatioN/ADividend YieldN/APrice Target$10.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Revance Therapeutics alerts: Email Address Revance Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside64.8% Upside$10.88 Price TargetShort InterestBearish14.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment-0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.18 out of 5 starsMedical Sector148th out of 924 stocksPharmaceutical Preparations Industry52nd out of 426 stocks 4.1 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageRevance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revance Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.93% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Revance Therapeutics has recently decreased by 4.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 2.0 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.Search Interest9 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revance Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Revance Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Revance Therapeutics Stock (NASDAQ:RVNC)Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesAugust 15, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Revance Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 15, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Sees Unusually-High Trading VolumeAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 15, 2024 | americanbankingnews.comWilliam Blair Reaffirms "Market Perform" Rating for Revance Therapeutics (NASDAQ:RVNC)August 15, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Rating Lowered to Hold at Piper SandlerAugust 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Shares Gap Up to $3.53August 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Downgraded by Needham & Company LLC to HoldAugust 14, 2024 | msn.comNeedham Downgrades Revance Therapeutics (RVNC)August 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Downgraded by HC WainwrightAugust 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by GuggenheimAugust 13, 2024 | markets.businessinsider.comMaintaining Hold on Revance Therapeutics Amid Merger Developments and Positive Sales ForecastAugust 13, 2024 | marketwatch.comRevance Therapeutics Shares Soar on Takeover by Crown LabsAugust 13, 2024 | markets.businessinsider.comAnalyst Holds on Revance-Crown Merger Amid Strategic Fit and Revenue ConcernsAugust 13, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNCAugust 12, 2024 | finance.yahoo.comCrown Laboratories, Revance Enter Merger AgreementAugust 12, 2024 | msn.comBotox Innovator Revance Therapeutics Goes Private In Over $900M DealAugust 12, 2024 | msn.comBotox rival Revance to go private in $924 million dealSee More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$10.88 High Stock Price Target$20.00 Low Stock Price Target$6.00 Potential Upside/Downside+64.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-323,990,000.00 Net Margins-117.88% Pretax Margin-124.66% Return on EquityN/A Return on Assets-41.05% Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.01 Sales & Book Value Annual Sales$234.04 million Price / Sales2.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.73) per share Price / Book-3.82Miscellaneous Outstanding Shares104,820,000Free Float99,122,000Market Cap$691.81 million OptionableOptionable Beta0.98 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 59)CEO & Director Comp: $1.26MMr. Tobin C. Schilke (Age 49)CFO & Principal Accounting Officer Comp: $731.58kMr. Dwight O. Moxie (Age 48)Chief Legal Officer & General Counsel Comp: $713.82kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSenior Director of Investor Relations & Corporate CommunicationsMs. Taryn ConwayVice President of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer of Global Therapeutics Franchise Lead Ms. Erica Jordan (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsStoke TherapeuticsNASDAQ:STOKArcturus TherapeuticsNASDAQ:ARCTHeron TherapeuticsNASDAQ:HRTXNurix TherapeuticsNASDAQ:NRIXGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCBought 823,658 shares on 8/21/2024Ownership: 2.681%Algert Global LLCSold 127,260 shares on 8/16/2024Ownership: 0.010%AQR Capital Management LLCBought 170,960 shares on 8/15/2024Ownership: 0.192%Daymark Wealth Partners LLCBought 30,000 shares on 8/15/2024Ownership: 0.073%The Manufacturers Life Insurance Company Bought 9,601 shares on 8/15/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions RVNC Stock Analysis - Frequently Asked Questions How have RVNC shares performed this year? Revance Therapeutics' stock was trading at $8.79 on January 1st, 2024. Since then, RVNC stock has decreased by 24.9% and is now trading at $6.60. View the best growth stocks for 2024 here. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.12. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. Who are Revance Therapeutics' major shareholders? Top institutional investors of Revance Therapeutics include Stonepine Capital Management LLC (2.68%), Federated Hermes Inc. (2.14%), Rice Hall James & Associates LLC (0.68%) and Renaissance Technologies LLC (0.55%). Insiders that own company stock include Mark J Foley, Tobin Schilke, Dustin S Sjuts, Dwight Moxie, Erica Jordan, Carey Oconnor Kolaja, Angus C Russell and Aubrey Rankin. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR) and Sorrento Therapeutics (SRNE). This page (NASDAQ:RVNC) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
